These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9527304)

  • 1. Selections from current literature: pharmacological treatment of obesity.
    Connolly J; Verni C; Trilling J; Kelso E; Shiesha S
    Fam Pract; 1998 Feb; 15(1):88-93. PubMed ID: 9527304
    [No Abstract]   [Full Text] [Related]  

  • 2. [Valvular heart disease and primary pulmonary hypertension associated with fenfluramine-phentermine].
    Wolf I; Mouallem M; Farfel Z
    Harefuah; 1998 Dec; 135(11):515-7. PubMed ID: 10911468
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants].
    Goldstein SE; Levy Y; Shoenfeld Y
    Harefuah; 1998 Dec; 135(11):489-92, 568. PubMed ID: 10911459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fen-phen manufacturers, not physicians, are liable.
    Allen S; Henderson J
    Tex Med; 2000 May; 96(5):62-4. PubMed ID: 10843016
    [No Abstract]   [Full Text] [Related]  

  • 5. Obesity and the diet pill dilemma.
    Healy BP
    J Womens Health; 1997 Aug; 6(4):391-2. PubMed ID: 9279828
    [No Abstract]   [Full Text] [Related]  

  • 6. Longitudinal effects of fenfluramine-phentermine use.
    Bhattacharyya S; Constantin C; Davar J; Mikhailidis D
    Angiology; 2007 Dec-2008 Jan; 58(6):772-3; author reply 774. PubMed ID: 18216387
    [No Abstract]   [Full Text] [Related]  

  • 7. Obesity and an abnormal ECG.
    Hancock EW
    Hosp Pract (1995); 1997 Sep; 32(9):19-20. PubMed ID: 9307592
    [No Abstract]   [Full Text] [Related]  

  • 8. Appetite suppressants and cardiac valvulopathy. Current clinical perspectives.
    Gross SB
    Adv Nurse Pract; 1999 Oct; 7(10):36-40. PubMed ID: 10808770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diet pills redux.
    Curfman GD
    N Engl J Med; 1997 Aug; 337(9):629-30. PubMed ID: 9271487
    [No Abstract]   [Full Text] [Related]  

  • 10. Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
    Anchors M
    Arch Intern Med; 1997 Jun; 157(11):1270. PubMed ID: 9183245
    [No Abstract]   [Full Text] [Related]  

  • 11. Death from irreversible pulmonary hypertension associated with short-term use of fenfluramine and phentermine.
    Dillon KA; Putnam KG; Avorn JL
    JAMA; 1997 Oct 22-29; 278(16):1320. PubMed ID: 9343461
    [No Abstract]   [Full Text] [Related]  

  • 12. Unusual hypotension and bradycardia in a patient receiving fenfluramine, phentermine, and fluoxetine.
    Rich JM; Njo L; Roberts KW; Smith KP
    Anesthesiology; 1998 Feb; 88(2):529-31. PubMed ID: 9477076
    [No Abstract]   [Full Text] [Related]  

  • 13. Bipolar depression associated with fenfluramine and phentermine.
    Zimmer JE; Gregory RJ
    J Clin Psychiatry; 1998 Jul; 59(7):383-4. PubMed ID: 9714271
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine.
    Mark EJ; Patalas ED; Chang HT; Evans RJ; Kessler SC
    N Engl J Med; 1997 Aug; 337(9):602-6. PubMed ID: 9271482
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug-induced pulmonary hypertension: must history repeat itself?
    Voelkel NF
    Pulm Pharmacol; 1996 Apr; 9(2):67-8. PubMed ID: 8880947
    [No Abstract]   [Full Text] [Related]  

  • 16. Complex vascular lesions at autopsy in a patient with phentermine-fenfluramine use and rapidly progressing pulmonary hypertension.
    Strother J; Fedullo P; Yi ES; Masliah E
    Arch Pathol Lab Med; 1999 Jun; 123(6):539-40. PubMed ID: 10383810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment of obesity with drugs.
    Hirsch J
    Am J Clin Nutr; 1998 Jan; 67(1):2-4. PubMed ID: 9440366
    [No Abstract]   [Full Text] [Related]  

  • 18. Fenfluramine and phentermine.
    Howlin D
    Ann Intern Med; 2001 Nov; 135(9):840-1. PubMed ID: 11694113
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease.
    Lepor NE; Gross SB; Daley WL; Samuels BA; Rizzo MJ; Luko SP; Hickey A; Buchbinder NA; Naqvi TZ
    Am J Cardiol; 2000 Jul; 86(1):107-10. PubMed ID: 10867106
    [No Abstract]   [Full Text] [Related]  

  • 20. The age-adjusted mortality rate from primary pulmonary hypertension, in age range 20 to 54 years, did not increase during the years of peak "phen/fen" use.
    Rothman RB
    Chest; 2000 Nov; 118(5):1516-7. PubMed ID: 11083718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.